Scott, in his SA article, made it more clear to investors, that PSDV has the platform tech systems that are broad in scope. Drug delivery, especially in ophthalmology, will enable this little company to produce products with the big pharmas. Scott further pointed out the evaluation agreement with HHS ; the possibilities for arthritis could be huge. Alimera, on the other hand has one drug and with few planned indications. Why should it have a greater market cap?